WASHINGTON, Sept. 19, 2024 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its tradipitant development program. On September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve…Original Article
FDA Declines to Approve Vanda’s Marketing Application for Tradipitant in Gastroparesis
